BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Press Releases

  Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

  September 11, 2024

   · 

  5 min read
• Business

  Novotech Honored with Frost & Sullivan’s 2024 Best Practices Company of the Year Award for Leadership in Biotech CRO Services

  September 11, 2024

   · 

  3 min read
• Press Releases

  Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 10, 2024

  September 11, 2024

   · 

  2 min read
• Press Releases

  Innovent Delivers Oral Presentation on Phase 1 Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer at the 2024 WCLC

  September 11, 2024

   · 

  8 min read
• Press Releases

  Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 10, 2024

  September 11, 2024

   · 

  2 min read
• Press Releases

  Terns Announces Pricing of Upsized $150.15 Million Public Offering

  September 11, 2024

   · 

  5 min read
• Press Releases

  Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)

  September 11, 2024

   · 

  23 min read
• Press Releases

  Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study

  September 11, 2024

   · 

  20 min read
• Press Releases

  Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial

  September 11, 2024

   · 

  26 min read
• Press Releases

  Oxford-Harrington Rare Disease Centre Appoints Influential UK Leader in Health Innovation Policy, Baroness Nicola Blackwood, to its Advisory Council

  September 11, 2024

   · 

  5 min read